Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 452, 541-542 (3 April 2008) | doi:10.1038/452541a; Published online 2 April 2008
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Postdoctoral Fellow / Research Associate
- Beth Israel Deaconess Medical Center/Harvard Medical School
- Boston, MA, USA
30 Doctoral Stipends for Outstanding Young Researchers
- Christian-Albrechts-Universitat zu Kiel
- Kiel, Germany
Drug resistance: The fight against fungi
André Goffeau1
Abstract
Although several drugs are available to combat often-deadly fungal infections, many of these pathogens have acquired multidrug resistance. Discerning how they have achieved this could help us hit back.
When we think of infectious agents, it is viruses and bacteria that first come to mind — fungi do not sound especially threatening. But opportunistic fungal infection is an emerging problem, particularly for immunocompromised patients such as those with AIDS and cancer, or those who have undergone organ transplants.
- André Goffeau is at the Institut des Sciences de la Vie, Université catholique de Louvain, Croix du Sud 5/15, 1349 Louvain-la-Neuve, Belgium.
Email: andre.goffeau@scarlet.be
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
A nuclear receptor-like pathway regulating multidrug resistance in fungiNature Article (03 Apr 2008)
An ATP-driven efflux pump is a novel pathogenicity factor in rice blast diseaseThe EMBO Journal Article (01 Feb 1999)
